EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes

Sandro La Vignera iD, Rosita A Condorelli iD

Pharmaceuticals · 06.08.2026 · 19 (8) · 1236

DOI: 10.3390/ph19081236 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 06.08.2026. Verfasst von Sandro La Vignera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is approved for weight management as both a weekly subcutaneous (s.c.) injection (2.4 mg) and a daily oral tablet (50 mg). Although head-to-head trials are lacking, the oral formulation offers potential advantages in adherence, patient preference, and accessibility. This systematic review critically appraised comparative and formulation-specific evidence to characterise the efficacy, safety, pharmacokinetics, and patient-reported outcomes of oral vs. s.c. semaglutide in adults with obesity or overweight with at least one weight-related comorbidity.

Methods

PubMed, Google Scholar, and SciSpace were searched from inception to June 2025, applying PRISMA 2020 guidelines. Eligibility criteria (PICO): adults with BMI ≥ 27 kg/m2; intervention, oral semaglutide (any dose); comparator, s.c. semaglutide or placebo; outcomes, body weight, BMI, cardiometabolic markers, adverse events, adherence. Risk of bias was assessed with RoB 2.0 (RCTs) and AMSTAR-2 (systematic reviews).

Results

Thirty studies met inclusion criteria (12 RCTs, nine systematic reviews/meta-analyses, five comparative/observational studies, four pharmacokinetic studies). OASIS 1 demonstrated −15.1% body weight reduction with oral semaglutide 50 mg at 68 weeks, comparable to s.c. semaglutide 2.4 mg (−14.9% in STEP 1). Both formulations significantly improved HbA1c, blood pressure, and lipid profiles. Oral bioavailability (~1%) requires co-administration with the SNAC absorption enhancer; s.c. bioavailability is ~89%. Oral semaglutide showed superior patient preference and equivalent adherence in needle-averse patients.

Conclusions

Oral semaglutide 50 mg is a clinically valid alternative to s.c. semaglutide for obesity management, offering equivalent efficacy and an improved patient experience for individuals who prefer needle-free treatment. Robust direct comparative trials are needed.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistOASIS 1STEP trialsadherenceobesityoral GLP-1RApharmacokineticssemaglutidesubcutaneous semaglutideweight loss

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

ORCID-Profile: Sandro La Vignera, Rosita A Condorelli

Zitieren

APA

La Vignera, S., & Condorelli, R. A. (2026). Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes. Pharmaceuticals, 19(8), 1236. https://doi.org/10.3390/ph19081236

Vancouver

La Vignera S, Condorelli RA. Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes. Pharmaceuticals. 2026;19(8):1236. doi:10.3390/ph19081236

BibTeX
@article{LaVignera2026,
  author = {La Vignera, Sandro and Condorelli, Rosita A},
  title = {Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1236},
  doi = {10.3390/ph19081236}
}
Kostenlos starten →